Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Day One Biopharmaceuticals ( (DAWN) ) just unveiled an announcement.
Day One Biopharmaceuticals reported a successful third quarter in 2024, driven by strong demand for its cancer therapy OJEMDA, which achieved $20.1 million in net revenue—a 145% increase from the previous quarter. The company ended the quarter with $558.4 million in cash and investments, and announced plans to advance its pipeline, including the upcoming clinical trial of DAY301. Additionally, Day One secured a lucrative licensing agreement with Ipsen, and anticipates further growth through new trials and expanded market reach.
Find detailed analytics on DAWN stock on TipRanks’ Stock Analysis page.
